{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:53:35Z","timestamp":1771876415244,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.3816\/clm.2004.n.017","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:25Z","timestamp":1221095425000},"page":"110-115","source":"Crossref","is-referenced-by-count":39,"title":["Results of a Phase II Multicenter Trial of Single-Agent Gemcitabine in Patients with Relapsed or Chemotherapy-Refractory Hodgkin's Lymphoma"],"prefix":"10.3816","volume":"5","author":[{"given":"Hemachandra","family":"Venkatesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Di Bella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Vellek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi A.","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Asmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2004.n.017_bib1","series-title":"Cancer Facts & Figures 2004","author":"American Cancer Society","year":"2004"},{"key":"10.3816\/CLM.2004.n.017_bib2","series-title":"Cancer Principles and Practice of Oncology","first-page":"2250","article-title":"Leukemias and Lymphomas of Childhood","author":"Weinstein","year":"2001"},{"issue":"suppl 5","key":"10.3816\/CLM.2004.n.017_bib3","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/annonc\/9.suppl_5.S103","article-title":"New drugs in the treatment of Hodgkin's disease","volume":"9","author":"Borchmann","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2004.n.017_bib4","first-page":"21a","article-title":"Phase II study with gemcitabine in pretreated patients with Hodgkin's (HD) and non-Hodgkin's lymphomas (NHL): Results of a multicenter study","volume":"16","author":"Santoro","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2004.n.017_bib5","first-page":"2627","article-title":"Gemcitabine is active in relapsed Hogkin's disease","author":"Lucas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.n.017_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1006478702342","article-title":"Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine","volume":"19","author":"Sezer","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.3816\/CLM.2004.n.017_bib7","first-page":"926","article-title":"Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients","volume":"17","author":"Zinzani","year":"2000","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2004.n.017_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1592\/phco.19.16.1331.30873","article-title":"Identification of a gemcitabine-warfarin interaction","volume":"19","author":"Kinikar","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.3816\/CLM.2004.n.017_bib9","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study","volume":"18","author":"Santoro","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2004.n.017_bib10","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.11582","article-title":"Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity","volume":"98","author":"Friedberg","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2004.n.017_bib11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1046\/j.1365-2141.2003.04226.x","article-title":"Gemcitabine, cisplatin and methylprenisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non- Hodgkin's lymphoma","volume":"120","author":"Chau","year":"2003","journal-title":"Brit J Haematol"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511700653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511700653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T22:59:09Z","timestamp":1545778749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511700653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S1526965511700653"],"URL":"https:\/\/doi.org\/10.3816\/clm.2004.n.017","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}